临床前生物分布与剂量学及人体生物分布比较18F-rhPSMA-7与单一异构体18F-rhPSMA-7.3
本研究在SCID小鼠中比较18F-rhPSMA-7与单一非对映异构体18F-rhPSMA-7.3的临床前剂量学,并利用47例18F-rhPSMA-7与33例18F-rhPSMA-7.3 PET/CT检查评估人体生物分布。两种显像剂剂量学均良好,按1小时排尿间隔注射370 MBq后辐射暴露低于5 mSv;18F-rhPSMA-7.3膀胱摄取显著更低,肿瘤摄取呈更高趋势。
要点
- 两种显像剂临床前剂量学均良好,按1小时排尿间隔注射370 MBq后辐射暴露低于5 mSv
- 18F-rhPSMA-7.3膀胱SUVmean显著低于18F-rhPSMA-7(2.0 vs 4.6,p < 0.001)
- 18F-rhPSMA-7.3肿瘤SUVmean为32.5 ± 42.7(n = 63个病灶),高于18F-rhPSMA-7的20.0 ± 20.2(n = 89个病灶)
核心结论
- 两种显像剂辐射剂量学均良好,按1小时排尿间隔注射370 MBq后辐射暴露低于5 mSv。
- 18F-rhPSMA-7.3较18F-rhPSMA-7膀胱摄取显著更低,肿瘤摄取呈更高趋势。
研究设计与样本
- 临床前剂量学:SCID小鼠注射25.6 ± 3.6 MBq 18F-rhPSMA-7或28.5 ± 4.8 MBq 18F-rhPSMA-7.3,每个时间点n = 3-6只,注射后10-300分钟多个时间点处死。
- 人体生物分布:使用18F-rhPSMA-7(n = 47)与18F-rhPSMA-7.3(n = 33)PET/CT检查估算。
- 18F-rhPSMA-7平均(范围)注射活度为324(236-424)MBq,18F-rhPSMA-7.3为345(235-420)MBq;采集时间分别为84(42-166)分钟与76(59-122)分钟。
主要发现
- 临床前剂量学:在3.5小时与1小时排尿间隔下,18F-rhPSMA-7外推总有效剂量分别为26.6与12.2 µSv/MBq,18F-rhPSMA-7.3分别为21.7与12.8 µSv/MBq。
- 人体SUVmean(18F-rhPSMA-7 vs 18F-rhPSMA-7.3):腮腺16.9 vs 16.2,下颌下腺19.6 vs 19.9,血池2.0 vs 1.9(p < 0.005),肺0.7 vs 0.7,肝7.0 vs 7.3,脾9.1 vs 8.4,肾32.4 vs 35.7,胰腺2.5 vs 2.8,十二指肠10.9 vs 11.0,骨1.1 vs 1.3,膀胱4.6 vs 2.0(p < 0.001)。
- 肿瘤SUVmean:18F-rhPSMA-7.3为32.5 ± 42.7(n = 63个病灶),高于18F-rhPSMA-7的20.0 ± 20.2(n = 89个病灶)。
关键数值与推荐
- 临床前剂量学:3.5小时排尿间隔下外推总有效剂量18F-rhPSMA-7为26.6 µSv/MBq,18F-rhPSMA-7.3为21.7 µSv/MBq;1小时排尿间隔下分别为12.2与12.8 µSv/MBq。
- 人体血池SUVmean 18F-rhPSMA-7为2.0 vs 18F-rhPSMA-7.3为1.9(p < 0.005)。
- 人体膀胱SUVmean 18F-rhPSMA-7为4.6 vs 18F-rhPSMA-7.3为2.0(p < 0.001)。
- 肿瘤SUVmean 18F-rhPSMA-7为20.0 ± 20.2(n = 89个病灶)vs 18F-rhPSMA-7.3为32.5 ± 42.7(n = 63个病灶)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as 18F-rhPSMA-7 are a new class of theranostic agents in clinical development for prostate cancer. We compared preclinical dosimetry and human biodistribution of 18F-rhPSMA-7 with that of single diastereoisomer form, 18F-rhPSMA-7.3. METHODS: Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10-300 min) post-injection of 25.6 ± 3.6 MBq 18F-rhPSMA-7 or 28.5 ± 4.8 MBq 18F-rhPSMA-7.3 (n = 3-6 mice per timepoint). Heart, lung, liver, spleen, pancreas, fat, stomach, small intestine, large intestine, kidney, muscle, bone, bladder, testicles, tail, and brain tissue were harvested, and urine and blood samples collected. Percentage of injected dose per gram was calculated. Absorbed doses were estimated with OLINDA/EXM 1.0. 18F-rhPSMA-7 (n = 47) and 18F-rhPSMA-7.3 (n = 33) PET/CT exams were used to estimate human biodistribution. Mean (range) injected activities were 324 (236-424) MBq versus 345 (235-420) MBq, and acquisition times were 84 (42-166) versus 76 (59-122) minutes for 18F-rhPSMA-7 versus 18F-rhPSMA-7.3, respectively. SUVmean was determined for background (gluteal muscle), normal organs (salivary glands, blood pool, lung, liver, spleen, pancreas, duodenum, kidney, bladder, bone) and up to three representative tumour lesions. Qualitative analyses assessed image quality, non-specific blood pool activity, and background uptake in bone/marrow using 3/4-point scales. RESULTS: Preclinical dosimetry revealed that at 3.5 h and 1 h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 µSv/MBq for 18F-rhPSMA-7 and 21.7 and 12.8 µSv/MBq for 18F-rhPSMA-7.3 respectively. Human biodistribution of both agents was typical of other PSMA-ligands and broadly similar to each other; SUVmean were 16.9 versus 16.2 (parotid gland), 19.6 versus 19.9 (submandibular gland), 2.0 versus 1.9 (blood pool, p < 0.005), 0.7 versus 0.7 (lungs), 7.0 versus 7.3 (liver), 9.1 versus 8.4 (spleen), 32.4 versus 35.7 (kidney), 2.5 versus 2.8 (pancreas), 10.9 versus 11.0 (duodenum), 1.1 versus 1.3 (bone) and 4.6 versus 2.0 (bladder; p < 0.001) for 18F-rhPSMA-7 versus 18F-rhPSMA-7.3, respectively. Tumour SUVmean was higher for 18F-rhPSMA-7.3 (32.5 ± 42.7, n = 63 lesions) than for 18F-rhPSMA-7 (20.0 ± 20.2, n = 89 lesions). CONCLUSIONS: Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1 h voiding interval, is less than 5 mSv after injection of 370 MBq. 18F-rhPSMA-7.3 showed significantly lower bladder uptake, and a higher uptake trend in tumours compared with 18F-rhPSMA-7.
引用
- Knorr K, Oh SW, Krönke M, et al. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3. EJNMMI Res. 2022. PMID: 35119557. doi:10.1186/s13550-021-00872-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。